Multi-targeted directed ligands for Alzheimer’s disease: design of novel lead coumarin conjugates by Repsold, B.P. et al.
Repsold, B.P. et al. (2018). Multi-targeted directed ligands for Alzheimer’s disease: design of 
novel lead coumarin conjugates.  
SAR and QSAR in Environmental Research, 29(3): 231 – 255 
http://dx.doi.org/10.1080/1062936X.2018.1423641 
 
 
University of the Western Cape Research Repository  douglas.oliver@nwu.ac.za      
 
Multi-targeted directed ligands for Alzheimer’s disease: design of 
novel lead coumarin conjugates 
 
B. P. Repsold, S. F. Malan, J. Joubert and D. W. Oliver 
 
Abstract 
Alzheimer’s Disease (AD) is a neurodegenerative disease characterized by central nervous 
system insults with progressive cognitive (memory, attention) and non-cognitive (anxiety, 
depression) impairments. Pathophysiological events affect predominantly cholinergic 
neuronal loss and dysfunctions of the dopaminergic system. The aim of the current study was 
to design multi-targeted directed lead structures based on the coumarin scaffold with 
inhibitory properties at two key enzymes in disease relevant systems, i.e. acetylcholinesterase 
(AChE) and monoamine oxidase B (MAO-B). Conventional and microwave synthetic 
methods were utilized to synthesize coumarin scaffoldbased novel morpholino, piperidino, 
thiophene and erucic acid conjugates. Biological assays indicated that the coumarin–
morpholine ether conjugate BPR 10 was the most potent hMAO-B inhibitor. The coumarin–
piperidine conjugates BPR 13 and BPR 12 were the most potent inhibitors of eeAChE at 100 
μM and 1 μM, respectively. Molecular modelling studies were conducted with Accelrys® 
Discovery Studio® V3.1.1 utilising the published hMAO-B (2V61) and hAChE (4EY7) crystal 
structures. Compound BPR 10 occupies both the entrance and substrate cavities of the active 
site of MAO-B. BPR 13 resides in both the peripheral anionic site (PAS) and the catalytic 
anionic site (CAS) of hAChE. This study demonstrated that the coumarin scaffold serves as a 
promising pharmacophore for MTDLs design. 
 
Introduction 
Alzheimer’s disease (AD) is categorized as the most dominant form of neurodegenerative disease 
leading to dementia. Common symptoms include a decline in cognition (learning and memory) 
but it also affects non-cognitive abilities (e.g. anxiety, depression, apathy and psychosis). A 2015 
survey revealed that, worldwide, 46.8 million people are living with dementia [1]. Statistics 
predict that, worldwide in 2050, an individual could develop AD every three seconds [2]. 
Pathologically AD progresses to affect limbic structures, subcortical nuclei and cortical regions, 
causing disturbance of multiple neurotransmitter systems. The most dominant neuronal loss is 
in the cholinergic system [3,4], in which the cholinergic neurons and the number of nicotinic 
acetylcholine receptors (nACHRs) declines in the hippocampus and cortex [5,6]. This hippocampal 
atrophy can spread to the amygdala [7]. Non-cognitive behavioural and neuropsychiatric symptoms 
often accompany AD [8] and usually arise from the dysfunction of the serotonergic and 
dopaminergic systems [8,9]. The characteristics of AD include the presence of extracellular 
plaques containing the beta-amyloid protein (Aβ42) and intracellular neurofibrillary tangles 
2 
 
(NFTs) of hyperphosphorylated tau protein with a further downstream effect of neuronal synapse 
degeneration [10]. 
 
No single ‘magic bullet’ exists to prevent or cure AD, and current treatments only provide 
symptomatic relief that doesn’t significantly address the underlying neurodegeneration and 
pathophysiology [11]. Currently approved treatment regimens include three acetylcholinest-erase 
(AChE) inhibitors (donepezil, rivastigmine and galantamine) and a non-competitive N-methyl-D-
aspartate (NMDA) antagonist (memantine). Usually, this is used in conjunction with a mood 
stabilizer (since AD isn’t limited to cognitive effects), resulting in a ‘cocktail’ of medication (Figure 
1). 
 
Medicinal chemistry research in the past generally focused on highly specific and selective 
compounds for single target interaction, also known as a one-molecule, one-target paradigm, 
and proved to be effective for disorders where a single target has been identified. As 
pharmacogenomics and other biochemical fields progressed, it became evident that the 
underlying mechanisms of disease are significantly more complex. Additionally, cells can 
compensate during drug intervention, by amongst others, the existence of parallel pathways [12]. 
Researchers began applying a new strategy based on the rationale that a single compound might be 
able to interact with multiple targets for the treatment of neurodegenerative diseases [13]. This 
approach is known as multi-target-directed ligands (MTDLs) (Figure 2). 
 
The aim of the current investigation was to design multi-target directed lead structures based on 
the coumarin scaffold. The purpose was to design compounds that inhibit both the cholinergic 
and dopaminergic systems by inhibiting the two key enzymes, i.e. acetyl-cholinesterase (AChE) and 
monoamine oxidase B (MAO-B). MAO-B inhibition has been closely associated with AD pathology, 
including the accompanied neuropsychiatric symptoms [8], anti-oxidant effects/oxidative stress 
generated by radical oxygen species (ROS) [13–15], Aβ aggregation inhibition [13,16], inhibition of β-
secretase [16], metal chelating activity [14,17] and the formation of tau aggregates [18]. The current 
investigation employed conventional and microwave-assisted synthetic methods; molecular 
modelling studies using the CDOCKER® module of Accelrys® Discovery Studio® V3.1.1 software 
(Dassault Systemes, BIOVIA Corp., San Diego, CA) utilizing the published hMAO-B (2V61) and hAChE 
(4EY7) crystal structures [19–22]; and biological evaluation of acetylcholinesterase (AChE) and 
monoamine oxidase B (MAO-B) inhibition by the newly synthesized compounds. 
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Design of conjugated coumarin scaffolds for Alzheimer’s disease 
The current study allows for the design of structures of coumarin conjugated with selected 
structural moieties, i.e. piperidine, morpholine, thiophene and erucic acid, which could 
potentially act as lead pharmacophoric MTDLs. The coumarin scaffolds (Figure 3) allow for 
conjugates with inhibition of AChE [23] characterized by dual interaction with both the active and 
peripheral sites of AChE. These compounds therefore also have the advantage of inhibiting AChE-
induced Aβ aggregation [24]. Coumarin structures have shown neuroprotective effects related to 
the interaction with β-secretase enzyme (BACE-1) [24], NMDA [25] and GABA-A receptors [26]. 
Additionally, coumarin’s other properties include protection against Aβ induced neuronal 
apoptosis, the regulation of L-type voltage-dependent calcium channels (VDCCs), which in turn 
causes a decrease of intracellular Ca2+ concentration [27], and counteracting oxidative stress 
induced by H2O2 [12–14,28]. 
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Conjugated moieties (piperidine, morpholine, thiophene and erucic acid) 
It has been found that piperdine (Figure 4) hybrids act as γ-secretase modulators, with high in vitro 
and in vivo anti-Aβ42 potency [29–32], Aβ42 aggregation inhibitors, AChE-induced Aβ 
aggregation [33], moderate to good AChE inhibitory activity [33,34] and positive metal-chelating 
ability [35]. Morpholine (Figure 4) contributes to decreased metal-induced (Fe and Cu) Aβ 
aggregation [36]; reduces Aβ toxicity, e.g. compound [(G3)-Mor] [37]; acts as an muscarinic 
receptor 1 agonist; enhances memory function in Alzheimer’s type dementia animal models; and 
modulates APP secretion [38,39]. It became evident that various thiophene (Figure 4) conjugates 
were potential AChE inhibitors [40–42]. Erucic acid (Figure 4) is a monounsaturated omega-9 fatty 
acid present in wallflower seed, rapeseed oil and canola (20–54%), and in mustard oil (42%). Erucic 
acid deficiency was detected in the early phase of neurodegeneration, and this strongly supported 
its use as a supplement to counteract AD progression [43]. Rapeseed proved to offer protection 
against Aβ-mediated cell death [44]. 
 
The coumarin structure with substitution options at positions 4, 7 and both (Figure 3) allows for 
unique chemical modifications resulting in novel structures that could serve as novel leads for 
further design and discovery research focussing on the MTDL approach for AD. Previous studies 
conducted with these substituted coumarins proved to be beneficial and provide valuable insight or 
clarify the rationale substitution preference into the structure activity relations (SAR) versus 
multiple target potency. 
 
Chemistry 
Materials and instrumentation 
Materials 
Starting materials were obtained from Sigma-Aldrich and Merck (Merck (Pty) Ltd, 
Modderfontein, Gauteng, Republic of South Africa (RSA)) and was used without further 
purification or converted to intermediate (more reactive) derivatives. All solvents used were 
anhydrous. Drying after extraction of the organic fractions was achieved using magnesium sulphate 
(MgSO4). 
 
Thin layer chromatography 
Thin layer chromatography (TLC) was carried out to determine the completeness of the reaction. 
Silica gel 60 sheets (Merck) containing UV254 fluorescent indicator were employed with the 
appropriate mobile phase for each reaction. The developed TLC sheets were observed under UV 
at a wavelength of 354 nm and the Rf values noted. 
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Melting points (Mp) 
A Büchi B-545® melting point apparatus (Labotec (PTY) Ltd (Büchi SA), Gauteng, RSA) was used to 
measure the Mp of all synthesised compounds. 
 
Mass spectra (MS) 
High resolution mass spectra (HRMS) and nominal mass spectra (MS) were obtained with a Bruker 
micrOTOF-Q II® mass spectrometer (Bruker South Africa (Pty) LTD, Sandton, Gauteng, RSA) in 
atmospheric-pressure chemical ionization (APCI) mode. 
 
Nuclear magnetic resonance (NMR) 
A Bruker Avance III 600® spectrometer, at frequencies of 600 MHz and 150 MHz, was used to record 
proton (1H) and carbon (13C) nuclear magnetic resonance (NMR) spectra, respectively. NMR 
experiments were conducted in CDCl3 and the chemical shifts reported in parts per million (δ) 
downfield from tetramethylsilane (TMS). Spin multiplicities are given as s (singlet), bs (broad 
singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quartet) or m (multiplet). The coupling 
constants (J) of the molecules’ atoms involved are given in Hz. 
 
Microwave-assisted synthesis 
A CEM Discovery® microwave reactor (Mintek, Randburg, Gauteng, RSA) fitted with a cooler, a 100 
mL flask with the suitable volume of solvent together with the adapted cooling system (as discussed 
below) was implemented (Figure 5). The advantages of microwave-assisted synthesis are: 
 
Extreme reaction rate acceleration that is associated with uncomplicated purification/isolation; 
Enhanced physicochemical properties; Yield improvement; Generation of new ‘potential products’ 
and Financial benefits, e.g. less solvent(s) is used, absence of expensive catalyst, etc. [45]. 
 
The disadvantages of microwave-assisted synthesis are:  
 
Limitation of solvent (because of the microwave-induced thermal effect). Solvents with a low 
boiling point are excited much more easily, which makes cooling/reflux much more 
uncontrollable, therefore we only choose solvents with a boiling point of 60°C and above; The 
generation of new product(s)/byproduct(s) can complicate the isolation of the desired products; 
Temperature regulation (sometimes cooling with nitrogen is required); and High investment costs 
[46]. 
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Synthetic routes 
Erucic acid–coumarin ester conjugates 
Erucic acid was firstly converted to its corresponding acyl chloride by means of oxalyl chloride in dry 
dichloromethane (DCM) to provide a more efficient nucleophilic attack on the respective coumarins 
(Scheme 1). 
 
Coumarin ether dimers 
Syntheses of dimers were done according to the classical Williamson etherification where the 7C, 
4MC and 4C (Scheme 2) served as nucleophiles and displaced the appropriate halide (1,3-dibromo-
propane and 1,4-dibromo-ethane) via the Sn2 reaction to produce the corresponding coumarin 
dimer. A basic salt (K2CO3) and a spatula point of KI were used as suitable ‘catalysts’ in acetonitrile 
(Scheme 2). 
 
Coumarin–thiophene ester conjugates 
Activating the thiophene acid in situ using N,N’-carbonyldiimidazole (CDI) in dry DCM provides 
the appropriate conditions for nucleophillic attack by 7C to produce the coumarin–thiophene 
conjugate (Scheme 3). 
 
 
 
http://repository.uwc.ac.za
7 
 
 
 
Coumarin–piperidine ethers and coumarin–morpholine ether conjugates 
Etherfication of 7C, 4M and 4C (Figure 3) with chloro-ethane piperidine and chloro-ethane 
morpholine through conventional heating produced the respective coumarin conjugates (Scheme 
4). 
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Synthetic methodology and compound characteristics 
Coumarin–erucic ester conjugates (BPR 1–BPR 3) 
A mixture of 3.36 mmol, 1139 mg, erucic acid and 3.36 mmol, 427 mg oxacyl chloride was 
suspended in 30 mL dry DCM and stirred for 2 h at room temperature (rt). The reaction turned 
yellowish and the corresponding erucyl chloride was formed. The excess oxacyl chloride as well as 
the DCM were removed under vacuum (60°C). The remaining erucyl chloride was suspended in 30 
mL tetrahydrofuran (THF) and, on an ice bath, 3.70 mmol, 600 mg, 7C and 7.40 mmol, 1022 mg, 2.2 
mol eqv. K2CO3 were added. The suspension was stirred for another 3–4 h at rt, filtered and purified 
using column chromatography with DCM: cyclohexane (3:1). It was dried, filtered and concentrated 
to obtain a white wax with a sweet odour (BPR 1). Yield: 860 mg, 1.78 mmol, 48.11%. 
 
BPR  1:  2-Oxo-2H-chromen-7-yl-docos-24-enoate 
Rf: 0.491. Mp: 53.8–54.5°C. 1H NMR (600 MHz, CDCI3 ): δ 7.67 (d, J = 9.5 Hz, 1H, H4); 7.46 (d, J = 8.4 Hz, 
1H, H5); 7.08 (d, J = 2.1 Hz, 1H, H6); 7.04–6.99 (m, 1H, H8); 6.37 (d, J = 9.5 Hz, 1H, H3); 5.32 (t, J = 4.7 
Hz, 2H, H24,25); 2.56 (t, J = 7.5 Hz, 2H, H13); 1.99 (m, 4H, H23,26); 1.77–1.70 (m, 4H,H14); 1.35–1.19 
(m, 28H, H15–22,27–32); 0.85 (t, J = 7.0 Hz, 3H, H33). C NMR (151 MHz, CDCI3): δ171.61 (C12); 160.35 
(C2); 154.68 (C9); 153.29 (C7); 142.84 (C4); 129.91 (C24); 129.85 (C25); 118.43 (C5); 116.56 (C6); 116.00 
(C10); 110.43 (C3); 34.32 (C8); 31.89 (C13); 30.92 (C31); 29.75–29.05(C15–23,26–29); 27.19(C30); 24.77(C14); 
22.67(C32); 14.18 (C33). MS: APCI-HRMS m/z: calculated for C31H46O4(MH
+), 483.3469, found 
481.3297. 
 
BPR 2: 2-Oxo-2H-chromen-4-yl docos-24-enoate 
Employing the above-mentioned procedure (Coumarin–erucic ester conjugates (BPR 1–BPR 3)), 
using 3.70 mmol, 600 mg, 4C and 7.40 mmol, 1022 mg K2CO3. Purification: column chromatography 
with DCM:cyclohexane (8:2). A white wax with a sweet odour formed. 
 
Rf: 0.585. Mp: 77–79°C. 1H NMR (600 MHz, CDCl3): δ 7.60 (dd, J = 7.9, 1.5 Hz, 1H, H5); 7.56                                                                
(m, 1H, H7); 7.34 (dd, J = 1, 0.6 Hz, 1H, H6); 7.30–7.26 (m, 1H, H8); 6.50 (s, 1H, H3), 5.33 (m, 2H, 
H26,27); 2.68 (t, J = 7.5 Hz, 2H, H13); 1.77 (m, 4H, H25,28); 1.39–1.17 (m, 28H, H15–24,29–32); 0.85 (t, 
J = 7.0 Hz, 3H, H33). 
13C NMR (151 MHz, CDCI3): δ 169.53 (C12); 161.50 (C4); 158.34 (C2); 153.65 (C9); 
132.71 (C7); 129.92 (C26); 129.83 (C27); 124.26 (C5); 122.66 (C6); 117.09 (C8); 115.53 (C10); 105.06 (C3); 
34.55 (C13); 30.92 (C31); 29.75–29.16 (C15–25); 29.00 (C28); 27.19 (C29); 26.89 (C30); 24.65 (C14); 
22.67 (C32); 14.10 (C33). MS: APCI-HRMS m/z: calculated for C31H46O4   (MH+), 483.3469, found 
481.303. Yield: 710 mg, 1.47 mmol, 39.73%. 
 
BPR  3:  4-Methyl-2-oxo-2H-chromen-7-yl  docos-25-enoate 
Employing the above-mentioned procedure (Coumarin–erucic ester conjugates (BPR 1–BPR 3)), 
using 3.40 mmol, 600 mg, 4M and 3.78 mmol, 1023 mg, K2CO3 were added, stirred for 14 h at rt. 
Purification: column chromatography with DCM:cyclohexane (7:1). A white wax with a sweet odour 
formed. 
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Rf: 0.528. Mp: 49–51.2°C. 1H NMR (600 MHz, CDCl3): δ 7.58 (d, J = 8.6 Hz, 1H, H5); 7.08 (d, J                                                           
= 2.2 Hz, 1H, H6); 7.04 (dd, J = 8.6, 2.3 Hz, 1H, H8); 6.24 (s, 1H, H3); 5.37–5.29 (m, 2H, H25,26); 2.56 (t, J 
= 7.5 Hz, 2H, H14); 2.41 (s, 3H, H11); 2.03–1.95 (m, 4H, H24,27); 1.77–1.70 (m, 2H, H15); 1.33–1.21 (m, 28H, 
H16–13,28–33); 0.85 (t, J = 7.0 Hz, 3H, H34). 
13C NMR (151 MHz, CDCI3): δ 171.64 (C13); 160.51 (C2); 
154.17 (C7); 153.18 (C9); 151.87 (C4); 129.90 (C25); 125.30 (C26); 118.11 (C5); 117.73 (C6); 114.45 (C10); 
110.44 (C3); 34.32 (C8); 31.89 (C14); 30.92 (C32); 29.75–27.19 (C27–31,16–24); 24.77 (C15); 22.67 (C33); 18.71 
(C11); 14.10 (C34). MS: APCI-HRMS m/z: calculated for C32H48O4  (MH+), 497.3625, found 497.3558. Yield: 
685 mg, 1.38 mmol, 40.59%. 
 
Coumarin–ether dimers (BPR 4–BPR 7) 
In a 50 mL flask, 3.08 mmol, 500 mg, 4C; 6.16 mmol, 852 mg K2CO3 and 3.08 mmol, 123 mg, NaH 
(60% dispersed in oil) were suspended in 6–8 mL dimethylformamide (DMF). It was stirred for 
30 min at rt, and to this stirred solution 1.54 mmol, 333 mg 1,4-dibromobutane was slowly added, 
and it was stirred for a further 20 h at 50°C. The mixture was filtered and 40–50 mL water was 
added to the suspension until a white precipitate formed. It was washed with cyclohexane to dispose 
of the excess DMF. Yield: 195 mg, 0.52 mmol, 16.88%. 
 
Alternative method 
In a 50 mL flask, 3.08 mmol, 500 mg, 4C; 6.16 mmol, 852 mg, K2CO3 and 3.08 mmol, 123 mg, NaH 
(60% dispersed in oil) were suspended in 30 mL anhydrous acetonitrile and stirred for 30 min at rt, 
and 1.54 mmol, 333 mg 1,4-dibromobutane was slowly added. Using the microwave reactor, the 
solution was irradiated according the following preferences: open vessel with cooling on; power 
200 W; temperature 45°C; run time 1:30 min; hold time 1:30 min. It was cooled down between 
sessions and irradiation repeated another three times. The reaction mixture was filtered, 
concentrated and recrystallized to yield white crystals (BPR 4). 
 
BPR  4:  4,4′-[Butane-1,4-diylbis(oxy)]bis(2H-chromen-2-one) 
Rf: 0.282. Mp: 173.2–175.2°C. 1H NMR (600 MHz, CDCl ): δ 7.77 (dd, J = 7.9, 1.4 Hz, 2H, H5,21); 7.56–
7.49 (m, 2H, H7,23); 7.28–7.20 (m, 4H, H8,24,6,22); 5.66 (s, 2H, H3,19); 4.29 (bs, 2H, H12,15); 2.23 (bs, 
2H, H13,14); 1.63 (s, 2H, H2O; CDCI3). 
13C NMR (151 MHz, CDCl3): δ 165.37 (C4,20); 162.77 (C2,18); 
153.26 (C9,25); 132.53 (C7,23); 123.90 (C5,21); 122.71 (C6,22); 116.82 (C8,24); 115.47 (C10,26); 90.66 
(C3,19); 68.66 (C12,15); 25.38 (C13,14). MS: APCI-HRMS m/z: calculated for C22H18O6 (MH+), 379.1176, found 
379.1206. Yield: 418 mg, 1.10 mmol, 35.71% (211.552% increase in yield). 
 
BPR  5:  4,4′-[Propane-1,3-diylbis(oxy)]bis(2H-chromen-2-one) 
Employing the above-mentioned procedure (Coumarin–ether dimers (BPR 4–BPR 7)), using 3.08 
mmol, 500 mg, 4C; 6.16 mmol, 852 mg, K2CO3 and 3.08 mmol, 123 mg, NaH (60% dispersed in oil). 
Next, 1.54 mmol, 311 mg 1,3-dibromopropane was slowly added. White crystals formed after 
recrystallization. 
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Rf: 0.378. Mp: 203.7–205°C. 1H NMR (600 MHz, CDCI ): δ 7.77 (dd, J = 7.9, 1.3 Hz, 2H, H5,18); 7.56–7.48 
(m, 2H, H7,20); 7.30 (m, 2H, H6,19), 7.25 (dd, J = 10.1, 5.0 Hz, 2H, H8,21); 5.72 (s, 2H,H3,24); 4.38 (t, 
J = 5.9 Hz, 2H, H13,15); 2.54 (m, 1H, H14); 1.63 (s, 2H, H2O; CDCI3). 
13C NMR (151 MHz, CDCI3): δ 
165.22 (C4,17); 162.66 (C2,23); 153.29 (C9,25); 132.62 (C7,20); 124.03 (C5,18); 122.73 (C6,19); 116.89 
(C8,21); 115.37 (C10,26); 90.87 (C3,24); 65.34 (C13,15); 27.95 (C14). MS: APCI-HRMS m/z: calculated for 
C21H16O6 (MH ), 365.1020, found 365.1034. Yield: 510 mg, 1.40 mmol, 45.45%. 
 
BPR  6:  7,7′-[Propane-1,3-diylbis(oxy)]bis(2H-chromen-2-one) 
Employing the above-mentioned procedure (Coumarin–ether dimers (BPR 4–BPR 7)), 
using3.08 mmol, 500 mg, 7C; 6.16 mmol, 852 mg, K2CO3 and 3.08 mmol, 123 mg, NaH (60% 
dispersed in oil) was suspended. Portion-wise, add 1.54 mmol, 311 mg 1,3-dibromopropane. White 
crystals formed after recrystallization. 
 
Rf: 0.359. Mp: 177–180°C. 1H NMR (600 MHz, CDCI ): δ 7.61 (d, J = 9.5 Hz, 2H,H); 7.35 (d,                                                    
J = 8.6 Hz, 2H,H5,23); 6.88 (dd, J = 8.6, 2.4 Hz, 2H, H6,24); 6.73 (s, 2H8,18); 6.23 (d, J = 9.5 Hz, 
2H,H3,21); 4.21 (t, J = 6.0 Hz, 4H, H13,15); 2.32 (m, 2H, H14); 1.64 (s, 2H, H2O; CDCI3). 
13C NMR (151 MHz, 
CDCI3): δ 161.89 (C7,17); 161.15 (C2,20); 155.82 (C9,25); 143.36 (C4,22), 128.80 (C5,23), 113.19 (C6,21); 
112.87 (C3,24), 112.36 (C10,26), 101.37 (C8,18), 64.66 (C13,15), 28.77 (C14). MS: APCI-HRMS m/z: 
calculated for C21H16O6  (MH+), 365.1020, found 365.1042. Yield: 405 mg, 1.11 mmol, 36.04%. 
 
BPR  7:  7,7′-[Propane-1,3-diylbis(oxy)]bis(4-methyl-2H-chromen-2-one) 
Employing the above-mentioned procedure (Coumarin–ether dimers (BPR 4–BPR 7)), using 3.41 
mmol, 600 mg, 4M; 6.82 mmol, 941 mg, K2CO3 and 3.08 mmol, 136 mg, NaH (60% dispersed in 
oil). To the solution, 1.70 mmol, 344 mg 1,3-dibromopropane was added, and it was stirred for 20 h 
at 50°C.Work up was done using column chromatography DCM:cyclohexane (9:1). White crystals 
formed after recrystallization. 
 
Rf: 0.208. Mp: 183.5–186°C. 1H NMR (600 MHz, CDCI ): δ 7.47 (d, J = 7.0 Hz, 2H, H); 6.86 (dd, J = 8.8. 
2.5 Hz, 2H, H6,22); 6.80 (d, J = 2.5 Hz, 2H,H8,24) 6.11 (s, 2H,H3,19); 4.58 (m, 4H, H13,15); 5.42 (dd, J = 
17.3, 1.4 Hz, 2H, H14); 2.37 (s, 6H, H11,27); 1.26 (s, 2H, H2O; CDCL3). 
13C NMR (151MHz, CDCI3): δ 
161.54 (C2,18); 161.29 (C7,23); 155.18 (C9,25); 152.52 (C4,20); 132.15 (C5,21); 125.51 (C10,26); 118.52 
(C6,22); 112.78 (C3,19); 112.00 (C8,24); 101.70 (C13,15); 69.20 (C14); 18.67 (C11,27). MS: APCI-HRMS m/z: 
calculated for C23H20O6  (MH+), 393.1333, found 391.2808. Yield: 495 mg, 1.26 mmol, 36.95%. 
 
Coumarin–thiophene ester conjugate (BPR 8) 
First, activation chemistry was implemented by suspending 3.90 mmol, 500mg, 2-thiophe- 
necarboxylic acid (TP) and 5.07 mmol, 822 mg, N,N′-carbonyldiimidazole (CDI) in 30 mL dry DCM. 
The solution was stirred for 2–4 h at rt and the solvent removed in vacuo. To the residue obtained, 3.90 
http://repository.uwc.ac.za
11 
 
16,15                       17,18                      19                                                                                            16   19        3 
mmol, 632 mg, 7C and 7.80 mmol 1078 mg, K2CO3 in 40 mL THF was added and it was stirred for 
an additional 20 h at 40°C. The reaction was cooled down, extracted with 2 × 60 mL ethyl acetate 
and dried using magnesium sulphate. The solution was filtered, dried and purified with column 
chromatography using DCM:cyclohexane (9:1). It was further concentrated and recrystallized – a 
white crystalline solid formed. 
 
BPR  8:  2-Oxo-2H-chromen-7-yl-thiophene-2-carboxylate 
Rf: 0.358. Mp: 145–146.2°C. 1H NMR (600 MHz, acetone): δ 8.04 (dd, J = 3.8, 1.2 Hz, 1H, H14); 8.03–
8.01 (m, 1H, H4); 8.01 (d, J = 1.1 Hz, 1H, H16); 7.78 (d, J = 6.6 Hz, 1H, H5); 7.36 (m, 1H, H15); 7.31 (dd, J = 
3.4, 2.1 Hz, 1H, H6); 7.30 (dd, J = 6.9, 1.4 Hz, 1H, H8); 6.42 (dd, J = 9.6, 3.9 Hz, 1H,H3); 2.12–1.96 (m, 
2H, H2O; acetone). 
13C NMR (151 MHz, DMSO): δ159.61 (C2); 154.11 (C7);152.51 (C12); 143.82 (C9); 
135.82 (C4); 135.65 (C13); 131.31 (C16); 129.45 (C5); 128.83 (C15); 118.72 (C6); 116.97 (C10); 115.74 (C3); 
110.35 (C8). MS: APCI-HRMS m/z: calculated for C16H18SO4 (MH
+), 273.0216, found 273.0218. Yield: 
402 mg, 1.48 mmol, 37.95%. 
 
Coumarin–piperidine ether conjugates (BPR 9, BPR 12, BPR 13) 
In a 100 mL flask equipped with a cooler, 7.40 mmol, 1362 mg, 1-(2-chloroethyl)-piperidine 
hydrochloride, 6.17 mmol, 1000 mg, 4C and 12.33 mmol, 1700 mg, K2CO3 were suspended in 75 mL 
dry acetonitrile. The reaction was refluxed for 10 h at 80°C, cooled down, filtered and evaporated 
under vacuum. The filtrate was then extracted with 100 mL water and 2 × 30 mL ethyl acetate. The 
combined organic fractions were collected, dried, filtered and concentrated to a volume of ~5 mL. 
Following recrystallizing at rt, bulky, yellow crystals formed (BPR 9). 
 
BPR  9:  4-[2-(Piperidin-1-yl)ethoxy]-2H-chromen-2-one 
Rf: 0.548. Mp: 117–118°C. 1H NMR (600 MHz, CDCI3): δ 7.78 (dd, J = 7.9, 1.5 Hz, 1H, H5); 7.54–7.50 
(m, 1H, H7); 7.29 (dd, J = 8.3, 0.6 Hz, 1H, H6); 7.24 (m, 1H, H8); 5.66 (s, 1H, H3); 4.23 (t, J = 5.8 Hz, 2H, 
H12); 2.86 (t, J = 5.8 Hz, 2H, H13); 2.51 (s, 4H, H15,16); 1.61–1.55 (m, 4H, H17,18);1.46–1.39 (m, 2H, 
H19). 
13C NMR (151 MHz, CDCI3: δ 165.51 (C4); 162.88 (C2); 153.30 (C9); 132.34 
 
(C7); 123.84 (C5); 123.04 (C6); 116.74 (C8); 115.69 (C10); 90.57 (C3); 67.70 (C12); 57.01 (C13); 55.01 (C16,15); 
25.95 (C17,18); 24.01(C19). MS: APCI-HRMS m/z: calculated for C16H19NO3  (MH+), 274.3270, found 274.1429. 
Yield: 635 mg, 2.32 mmol, 31.35%. 
 
BPR  12:  7-[2-(Piperidin-1-yl)ethoxy]-2H-chromen-2-one 
Employing the above-mentioned procedure (Coumarin–piperidine ether conjugates (BPR 9, BPR 
12, BPR 13)), 6.17 mmol, 1135 mg, 1-(2-chloroethyl) piperidine hydrochloride; 6.17 mmol, 1000 mg, 
7C and 12.33 mmol, 1705 mg K2CO3. Yellow crystals formed after recrystallization. 
Rf: 0.164. Mp: 89.4–90.5°C. 1H NMR (600 MHz, CDCI3): δ 7.60 (d, J = 9.5 Hz, 1H, H4); 7.33 (d,                                                            
J = 8.6 Hz, 1H, H5); 6.82 (dd, J = 8.6, 2.4 Hz, 1H, H6); 6.79 (d, J = 2.4 Hz, 1H, H8); 6.21 (d, J = 9.5 Hz, 1H, 
H3); 4.12 (t, J = 6.0 Hz, 2H, H12); 2.76 (t, J = 6.0 Hz, 2H, H13); 2.47 (bs, 4H, H15,16); 1.60–1.55(m, 4H, 
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H17,18); 1.42 (bs, 2H, H19). 
13C NMR (151 MHz, CDCI3): δ 162.05 (C7); 161.21 (C2); 155.81 (C9); 143.38 
(C4); 128.67 (C5); 113.03 (C3); 112.98 (C6); 112.50 (C10); 101.48 (C8); 66.63 (C12); 57.58 (C13); 55.06 
(C15,16); 25.88 (C17,18); 24.09 (C19). MS: APCI-HRMS m/z: calculated for C16H19NO3 (MH
+), 
274.1438, found 274.1434. Yield: 307 mg, 1.12 mmol, 18.15%. 
 
BPR   13:   4-Methyl-7-[2-(Piperidin-1-yl)ethoxy]-2H-chromen-2-one 
Employing the above-mentioned procedure (Coumarin–piperidine ether conjugates (BPR 9, BPR 
12, BPR 13)), using 3.41 mmol, 1600 mg, 4M and 6.81 mmol, 941 mg, K2CO3. To this solution, 4.09 
mmol, 752 mg, 1-(2-chloroethyl) piperidine hydrochloride was added. Bulky, yellow crystals formed 
after recrystallization. 
 
Rf: 0.315. Mp: 102–104°C. 1H NMR (600 MHz, CDCI3): δ 7.44 (d, J = 8.8 Hz, 1H, H5), 6.82 (dd,                                                  
J = 8.8, 2.4 Hz, 1H, H6), 6.76 (d, J = 2.4 Hz, 1H, H8), 6.08 (d, J = 0.9 Hz, 1H, H3), 4.12 (t, J = 5.9 Hz, 2H, 
H13), 2.76 (t, J = 5.9 Hz, 2H, H14), 2.48 (bs, 4H, H16,17), 2.35 (d, J = 1.0 Hz, 3H, H11), 1.58 (m,4H, 
H18,19), 1.41 (bs, 2H, H20). 
13C NMR (151 MHz, CDCI3): δ 161.77 (C7); 161.23 (C2); 155.13 (C9); 152.48 
(C4), 125.42 (C5), 113.52 (C3), 112.56 (C6), 111.85 (C10), 101.48 (C8), 66.44 (C12), 57.52 (C13), 55.00 
(C16,17), 25.76 (C18,19), 24.00 (C20), 18.60 (C11). MS: APCI-HRMS m/z: calculated for C17H21NO3 
(MH+), 288.1594, found 288.1593. Yield: 810 mg, 2.82 mmol, 82.70%. 
 
Coumarin–morpholine ether conjugates (BPR 10, BPR 11, BPR 14) 
BPR  10:  4-[2-(Morpholin-4-yl)ethoxy]-2H-chromen-2-one 
Using a 100 mL flask, 7.40 mmol, 1378 mg, 4-(2-chloroethyl) morpholine hydrochloride; 6.17 mmol, 
1000 mg, 4C and 12.33 mmol, 1.70 mg, K2CO3 were combined with a mixture of 75 mL anhydrous 
acetonitrile and 5 mL acetone. The reaction was refluxed at 80°C for 5 h, cooled down, filtered and 
evaporated to dryness. The filtrate was extracted with 100 mL water and 2 × 30 mL ethyl acetate. 
The organic fractions were combined, dried and filtered. The filtrate was concentrated and 
recrystallized at 5°C. Dark, yellow needles formed (BPR 10). 
 
Rf: 0.622. Mp: 121.3–122°C. 1H NMR (600 MHz, CDCI3): δ 7.76 (dd, J = 7.9, 1.5 Hz, 1H, H5); 7.54–7.50 
(m, 1H, H7); 7.29 (d, J = 8.3 Hz, 1H, H6); 7.27–7.23 (m, 1H, H8); 5.66 (s, 1H, H3); 4.24 (t, J = 5.5 Hz, 2H, 
H12); 3.72–3.69 (m, 4H, H17,18); 2.89 (t, J = 5.5 Hz, 2H, H13); 2.60–2.56 (m, 4H, H15,16). 13C NMR (151 
MHz, CDCI3): δ 165.38 (C4); 162.75 (C2); 153.28 (C9); 132.48 (C7); 123.86 (C5); 122.92 (C6); 116.78 (C8); 
115.57 (C10); 90.63 (C3); 67.45 (C17,18); 66.86 (C12); 56.69 (C13); 53.99 (C15,16). MS: APCI-HRMS m/z: 
calculated for C15H17NO4  (MH+), 276.1230, found 278.1229. Yield: 583 mg, 2.18 mmol, 29.46%. 
 
BPR  11:  7-[2-(Morpholin-4-yl)ethoxy]-2H-chromen-2-one 
Following the same procedure (Coumarin–morpholine ether conjugates (BPR 10, BPR 11, BPR 14)) 
as above, using 6.16 mmol, 1705 mg, 4-(2-chloroethyl) morpholine hydrochloride; 6.17 mmol, 1000 
mg, 7C and 12.33 mmol, 1170 mg, K2CO3. Yellow needles formed after recrystallization. 
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Rf: 0.216. Mp: 118.6–119.1°C. 1H NMR (600 MHz, CDCl3,): δ 7.61 (d, J = 9.5 Hz, 1H, H4); 7.34                                                               
(d, J = 8.6 Hz, 1H, H5); 6.83 (dd, J = 8.6, 2.4 Hz, 1H, H6); 6.79 (d, J = 2.4 Hz, 1H, H8); 6.23 (d, J = 9.5 Hz, 
1H, H3); 4.13 (t, J = 5.6 Hz, 2H, H12); 3.74–3.68 (m, 4H, H17,18); 2.81 (t, J = 5.6 Hz, 2H, H13); 2.56 (s, 4H, 
H15,16). 
13C NMR (151 MHz, CDCl3): δ 161.87 (C7); 161.14 (C2); 155.81 (C9); 143.34 (C4); 128.74 (C5); 
113.19 (C10); 112.97 (C6); 112.63 (C3); 101.43 (C8); 66.85 (C17,18); 66.40 (C12); 57.28 (C13); 54.07 (C15,16). 
MS: APCI-HRMS m/z: calculated for C15H17NO4  (MH+), 276.1230, found 276.1217. Yield: 709 mg, 2.58 
mmol, 41.88%. 
 
BPR 14: 4-Methyl-7-[2-(morpholin-4-yl)ethoxy]-2H-chromen-2-one 
Employing the above-mentioned procedure (Coumarin–morpholine ether conjugates (BPR 10, BPR 
11, BPR 14)), using 4.09 mmol, 761 mg, 4-(2-chloroethyl) morpholine hydrochloride; 3.41 mmol, 600 
mg, 4M and 6.81 mmol, 941 mg, K2CO3. Yellow needles formed after recrystallization. 
 
Rf: 0.381. Mp: 110.4–112.4°C. 1H NMR (600 MHz, CDCI3): δ 7.45 (d, J = 8.8 Hz, 1H, H5), 6.82                                                                
(dd, J = 17.4, 8.7 Hz, 1H, H6), 6.76 (d, J = 7.5 Hz, 1H, H8), 6.09 (d, J = 0.9 Hz, 1H, H3), 4.13 (t, J =5.6 Hz, 
2H, H13), 3.78–3.60 (m, 4H, H18,19), 2.80 (t, J = 5.6 Hz, 2H, H14), 2.56 (m, 4H, H16,17), 2.34(dd, J = 
16.2, 0.9 Hz, 3H, H11). 
13C NMR (151 MHz, CDCI3): δ 161.60 (C7), 161.20 (C2), 155.12 (C9), 152.49 (C4), 
125.49 (C5), 113.64 (C10), 112.58 (C6), 111.95 (C3), 101.40 (C8), 66.74 (C13), 66.20 (C18,19), 57.23 (C14), 
53.99 (C16,17), 18.60 (C11). MS: APCI-HRMS m/z: calculated for C16H19NO4 (MH
+), 290.1387, found 
290.1380. Yield: 390 mg, 1.35 mmol, 39.59%. 
 
Biological evaluation 
MAO-B inhibition 
A fluorometric assay, based on MAO-B oxidization of kynuramine to 4-hydroxyquinoline, was 
used to measure the enzyme activities with recombinant human MAO-B (hMAO-B) as enzyme 
source and kynuramine as substrate [47]. The concentrations of the 4-hydroxyquinoline produced 
were measured with a fluorescent spectrophotometer (excitation wavelength of 310 nm and an 
emission wavelength of 400 nm). The fluorescence intensity decreased as 4-hydroxyquinoline 
production is reduced by the MAO-B test inhibitors. The inhibition potencies were expressed as IC50 
values. 
 
Instrumentation, consumables and data processing 
The following were obtained from Sigma Aldrich: Kynuramine.2HBr, microsomes expressed in 
baculovirus infected Boyce Thompson Institute (BTI) insect cells [48] containing recombinant 
MAO-B (5 mg/mL), NaOH and DMSO. A Varian Cary Eclipse® fluorescence spectrophotometer was 
(Agilent Technologies South Africa, Johannesburg, Gauteng, RSA) utilized for fluorescence 
spectrophotometry. GraphPad® Prism® V.5.03 software (GraphPad Software, Inc., La Jolla, CA) was 
utilized for data processing. The non-parametric test application was used for significance 
comparability. 
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Methodology 
Recombinant hMAO-B (5 mg/mL) was stored at −70°C. The incubations were prepared in 500 μl 
potassium phosphate buffer (pH = 7.4). Various concentrations of the test inhibitor (0–100 μM), in 
4% DMSO as co-solvent was prepared. Kynuramine (30 μM) served as substrate and was added to each 
incubation. hMAO-B (0.0075 mg/ml) was then added and the reactions were incubated for 20 min 
at 37°C. The reaction was terminated by adding 400 μL NaOH (2 N), and distilled water (1000 
μL) was added to each reaction. It was centrifuged (16,000 g) for 10 min at rt to produce a 
supernatant. Concentration measurements of 4-hydroxyquinoline for the incubations were 
carried out using a Varian Cary Eclipse® fluorescence spectrophotometer (settings: medium 
photomultiplier tube (PMT) voltage with the excitation and emission slit widths set to 5 mm). 
The supernatant’s fluorescence was measured at an excitation wavelength of 310 nm and an 
emission wavelength of 400 nm. The initial rate of oxidation was plotted against the logarithm of 
the inhibitor concentration ([I]) and the IC50 values were determined from the sigmoidal dose–
response curves. Different inhibitor concentrations spanning at least three orders of magnitude 
were used for each sigmoidal curve (0; 0.1, 0.3; 1; 3; 10; 30; 100 μM). The inhibition data were 
fitted to the one site competition model [49] incorporated in the GraphPad® Prism® software 
package. The IC50 values were determined in triplicate and are expressed as mean ± standard 
deviation (SD). As a positive control, we used (R)-Deprenyl for its known MAO-B selectivity of 0.020 
μM [50] and parent compounds 7-hydroxycoumarin (umbelliferone) because of its known MAO-B 
inhibitory activity of 28.583 μM [51]. 
 
AChE – inhibition 
Employing an adapted version of the volumetric method using 5,5′dithiobis(2-nitrobenzoic acid) 
(DTNB) [52], the test compounds’ inhibitory activity against acetylcholinesterase from 
Electrophorus electricus (electric eel) (eeAChE) was spectrophotometrically evaluated. It is based on 
the rationale of eeAChE hydrolysis of DTNB, which is measured at 405 nm. 
 
Instrumentation, consumables and data processing 
The following were purchased from Sigma Aldrich: 5,5-dithio-bis-2-nitrobenzoic acid (DTNB), 396.3 
g/mol)); acetylthiocholine iodide (289.18 g/mol); eeAChE (500 UN); albumin from bovine 
serum (BSA); trizma hydrochloride reagent grade (157.60 g/mol); DMSO and NaOH. The Corning 
96-well flat transparent plates were acquired from BioRad (Bio-Rad Laboratories Ltd., Johannesburg, 
Gauteng, RSA) and a Rayto 6100® microplate reader (Rayto Life and Analytical Sciences Co., Ltd., 
Shenzhen, P.R. China) (filter for 405 nm) was utilized. All data analysis and calculations were done 
using Prism 4.03® (GraphPad®, La Jolla, CA). Data analysis was carried out using the Student 
Newman Keuls multiple range tests and the level of significance was accepted at p < 0.05. Tacrine 
[100 uM] was used as positive control. The data in Table 2 was obtained using equation (1). 
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Methodology 
Stock solutions of test compounds (1 μM and 100 μM) were prepared by dissolving it in DMSO 
and it was refrigerated until use. Trizma-hydrochloride buffer was prepared (pH adjusted to 8 
with diluted NaOH) and refrigerated until use. eeAChE (500 UN) was dissolved in 22.727 mL of 
Triz-buffer (38.43 nm), pre-aliquoted (500 μL) and frozen. Thus, the final concentration of the 
aliquots contains 22 UN/mL in 34.43 mM Tris. Acetylthiocholine iodide (15 mM–5 mL, 21.69 mg), 
DTNB (1.5 mM–10 mL, 5.94 g) and eeAChE (0.22 units/mL in 50 mM Tris-HCl and BSA 0.1%) were 
prepared directly preceding the assay and protected from light. Continuous thawing and refreezing 
of the above is not advisable. Then, 148 μL DTNB and 50 μL of eeAChE solution was added to each of 
the required wells on the 96-well plate. DMSO (2 μL) was added to the control followed by the 
addition of 2 μL of the test compound stock solutions in consecutive wells to give test 
concentrations of 100 μM and 1 μM. The plate was incubated at 25°C for 5 min. Acetylthiocholine 
iodide (30 μL) solution was added to the respective wells by means of a multipipet. Absorbance was 
measured at 405 nm every 60 s for 20 min using the Rayto® 6100 microplate reader. The activity 
(absorbance) was calculated and expressed as a percentage. To obtain a volume of 2000 μL of 0.22 
units/mL, 50 mM Tris, 0.1% BSA (sufficient for 40 × 200 μL wells), 1 aliquot of eeAChE was thawed, 
20 μL of the enzyme was used, and 1980 μL Tris (50.12 nM–5 mL, 39.50 mg) and 0.002 g BSA were 
added. To compensate for the DMSO effect on activity, the concentration of DMSO was kept at 1% 
throughout the assays. This was achieved by the amount of DMSO added to a final volume of 200 
μL in the wells, which was maintained at 2 μL (1%). 
 
Biological results 
The results of the enzyme inhibition activity studies are present in Tables 1 and 2 and Figures 
6–8. All the synthesized compounds were included in the biological inhibition studies (Figure 9). 
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MAO-B inhibition 
The results of the enzyme inhibition activity studies are presented in Table 1 and Figure 6. 
 
Compounds BPR 2–8 (Figure 9) and 4C (Figure 3) were devoid of MAO-B inhibitory activity. MAO-B 
inhibition activity was enhanced by nearly one log unit by conjugation of 7C (Figures 3 and 6, Table 1; 
IC50 = 28.583 μM) to erucic acid to yield the coumarin ester, BPR 1 (Figures 6 and 6 and 9, Table 1; 
IC50 = 3.680 μM), and with the sp carbon ‘spacer’ to yield coumarin ethers of morpholine BPR 11 
(Figures 6 and 9, Table 1; IC50 = 9.758 μM) and piperidine BPR 12 (Figures 6 and 9, Table 1; IC50 = 
9.209 μM). Compared to the parent structure, the 4MC conjugates (Table 1, Figure 6; IC50 = 94.327 
μM) also revealed a significant increase in activity with the sp2 carbon ‘linker’ and coumarin ether 
conjugates of piperidine BPR 13 (Figures 6 and 9, Table 1; IC50 = 3.093 μM) and morpholine BPR 14 
(Figures 6 and 9, Table 1; IC50 = 2.326 μM). Although 4C exhibited the lowest inhibition activity, its 
ether conjugates with piperidine and morpholine, BPR 9 and BPR 10 (Figures 6 and 9, Table 1; IC50 = 
21.720 μM and 0.372 μM) showed activity and produced the most potent compound, BPR10, the 4-
hydroxycoumarin–morpholine conjugate). 
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eeAChE inhibition 
The results of the enzyme inhibition activity studies are present in Table 2 and Figures 7 and 8. 
 
The results of the AChE inhibitory activity and structures of the newly synthesized compounds 
(Figure 9) are presented in Table 2. All of the synthesized compounds revealed weaker AChE potency 
than the positive control tacrine at both 100 μM and 1 μM. 
 
The coumarin scaffolds used in this study (7C, 4MC, 4C) do show some activity but were significantly 
less than the control tacrine. The conjugated coumarine compounds exhibited more promising 
activities when compared with the various scaffold. 
 
 
 
http://repository.uwc.ac.za
18 
 
 
 
 
 
The results show that the piperidine compounds, i.e. BPR 12 and BPR 13 (Figures 7, green bar, and 9, 
Table 2) presented the most promising activity in the AChE inhibition study of 30.90% and 
21.56%, respectively, at 1 μM. For the coumarin–erucic acid conjugates, BPR 2 (Figures 7, green bar, 
and 9) showed mild activity at 1 μM of 22.460%. Coumarin–morpholine conjugate BPR 10 (Figures 
7, blue bar, and 9, Table 2) was less active at 14.61% inhibition at1 μM. 
 
Data from the study at the higher concentration, 100 μM, revealed eeAChE inhibition of 75.81% for 
tacrine (positive control). The piperidine compounds were the most active of all the conjugates at 
100 μM. The piperdines BP R12 and BPR13 (Figures 8, green bar, and 9, Table 2) demonstrated the 
highest activity in the AChE inhibition study with 52.90% and 57.43% inhibition, respectively. 
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BPR 9 revealed the weakest activity of the piperidine series with 27.77% at 100 μM (Figures 8, blue 
bar, and 9, Table 2). 
 
The current results demonstrate that compounds BPR 13 (57.43% at 100 μM and 21.56% at 1μM), BPR 
12 (52.90% at μM and 30.90% at 1μM) and BPR 2 (22.46% at 1 μM) are the most promising coumarin 
conjugates (Figures 7–9, Table 2 Graphs 2 and 3). 
 
Molecular modelling 
The Material Studio® Discovery Studio® V3.1.1 software package (2012) with the CDOCKER® 
application was used. The method can be summarized in three parts, namely: preparing the protein, 
preparing the ligands, and docking and scoring. 
 
Protein preparation 
The appropriate protein crystal structures 4EY7 [22] (crystal structure of recombinant human AChE 
in complex with donepezil) and 2V61 [20] (crystal structure of human MAO-B in complex with the 
selective inhibitor 7-(3-chlorobenzyloxy)-4-(methyl amino) methyl coumarin) were downloaded 
from the Protein Data Bank (www.rcsb/pdb.org). The downloaded files were imported into 
Discovery Studio® and the protein report was used to confirm and check for any irregularities 
(crystallographic data, missing regions, alternate conformations, ligand co-crystallized, invalid 
residues, gaps in chains, etc.). The Prepare Protein® function was used to correct the irregularities 
mentioned above (when applicable). The co-crystallized ligand was removed and the protein was 
then typed with CHARMm® (Chemistry at Harvard Macromolecular Mechanics (charmm), 
Cambridge, MA) forcefield (Partial Charge: Momany and Rone), which assigned partial charges 
to the structures, and it was then saved. Subsequently, the ionization and protonation state was 
optimized using ‘Protonate only the Protein’ and ‘Calculate Protein Ionization and Residue pK’ with 
settings: pH Rang (0–14). The proteins were minimized (to correct for any potential steric overlap 
due to the structures’ van der Waals interactions). Minimization settings: max steps 5000; implicit 
solvent model: distance-dependent dielectric for 4EY7 and generalized born with implicit 
membrane for 2V61 was used (since MAO-B is membrane bound). After completion of these 
modelling setup preparations the structures were saved. 
 
Ligand preparation 
In a new window, the sketching function was used to sketch the ligands. Hydrogens were added, 
and the geometry ‘cleaned’ (placing the structures in the correct and optimal conformation 
regarding their atomical angles). The ‘Prepare Ligands’ utility was used with settings to true change 
ionization, generate tautomers and correct for valencies according to the accurate settings, and the 
file was saved. 
 
Docking 
The prepared protein was opened and typed with CHARMm® force field. The prepared ligand file was 
recalled. In CDOCKER®, the prepared protein and prepared ligand were loaded, and docked with 
random conformation set to 200, heating target temperature to 900 K and use full potential to true. 
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The best poses (selected according the highest CDOCKER score of the docked ligand within the 
active site of the protein and the prominent side chains was documented and interpreted (according 
to Accelrys® Discovery Studio® V3.1.1 protocols, 2012). The CDOCKER® energy is a quantitative 
indication of the ligand pose best accepted by the protein and includes numerous mathematical 
models. 
 
Results of the molecular modelling studies 
MAO-B docking 
The pyrone ring of the coumarin–morpholine conjugate (BPR 10) revealed numerous interactions 
with pivotal residues in the substrate cavity. Hydrogen binding (distance = 2.015307 Å; angle = 
109.461123°) with CYS172 (dotted white line), π interaction (distance = 6.514040 Å; angle = 
22.164892°) with TYR398 (orange line) and π-Sigma interaction (distance = 2.911005 Å; angle = 
27.035908°) with LEU171 (orange line) (Figure 10). 
 
The significance of TYR398 and TYR435, which directs a navigation path for the inhibitor towards 
the flavin adenine dinucleotide (FAD) (Figure 10) is evident. This corresponds with the ‘guidance’ 
towards the active site’s aromatic cage observation by Akyüz et al. [53]. 
 
AChE docking 
BPR 2 and BPR 13 were docked into hAChE to elucidate the binding mode of these novel inhibitors. 
The interactions with the protein’s residues for each compound are described. 
 
Since AChE contains a long narrow gorge that leads towards the catalytic anionic site (CAS) (see 
below), the elongated fatty acid chain of BPR 2 was preferred, rather than a steric bulky conjugate. 
Thus, the coumarin entity of BPR 2 occupied the peripheral anionic site (PAS) while the erucic 
acid enitity was pushed in through the gorge into the CAS (Figures 11 and 12). The rest of the 
elongated lipophilic entity was influenced by the neighbouring residues and fitted into the gorge to 
reach the CAS (although no further interactions were observed). 
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Two hydrogen bonds between the pyrone ring of BPR 2 and HIS287 were observed (Figure 
12; yellow arrow; dotted orange and green line) with the lipophillic entity stretching towards 
the CAS (Figure 12; blue sphere) through the gorge. 
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The molecular modelling investigation of selected coumarin conjugates (BPR 2 and BPR 13 for 
hACHE and BPR 10 for MAO-B) showed the potential of these conjugates to interact with these 
enzymes as targets for the treatment of Alzheimer’s disease. The aromatic ring scaffold of coumarin 
has clearly been shown to be an important pharmacophore moiety for π–π interactions with 
TYR283 and TRP341 in the PAS region of hAChE. Hydrogen bond formation has also been observed 
with residual TYR72. Two hydrogen bonds between the pyrone ring of BPR 2 and HIS287 (yellow 
arrow; dotted orange and green lines) with influential neighbouring atoms (line models) are 
illustrated for compound BPR 2 (Figure12). 
 
Two π–π interactions for BPR 13 are shown, the one between TYR341 (Figure 13) and the phenyl ring 
(orange line) (distance = 3.802244 Å; angle = 19.229446°) and the other between the pyrone ring and 
TRP341 (violet line) (distance = 4.869986 Å; angle = 7.121048°). 
 
Discussion 
The coumarin–morpholine ether conjugate, BPR 10 (4-[2-(morpholin-4-yl)ethoxy]-2H- 
chromen-2-one) proved to be the most promising hMAO-B inhibitor (IC50 = 0.372 μM). The 
coumarin–piperidine conjugates BPR 13 (4-methyl-7-[2-(piperidin-1-yl)ethoxy]-2H-chromen-2-
one) and BPR 12 [(7-[2-(piperidin-1-yl)ethoxy]-2H-chromen-2-one)] were the most potent 
inhibitors of eeAChE, with an inhibitory activity of 57.43% at 100 μM and 30.90% at 1 μM, 
respectively. 
 
Docking studies revealed that the morpholine–coumarin compound BPR 10 was able to occupy 
both the entrance and substrate cavities of MAO-B’s active site, with the coumarin moiety residing 
in the substrate cavity, while the morpholine moiety resides in the entrance cavity. BPR 10 shows π-
interactions with residues of CYS172, LEU171 and ILE198, and a relatively strong H-bond is present 
between the pyrone ring and CYS172. The coumarin entity of this compound is well positioned in 
the ‘aromatic cage’ of the substrate cavity. BPR 13 occupied both the PAS and the CAS of hAChE, 
with the coumarin positioned in the PAS region, the linker in the gorge (between the PAS and CAS 
regions) and the piperdine entity in the CAS region. BPR 13 formed π-interactions with TRP286 and 
TYR341, and an H-bond with TYR72 in the PAS. 
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A series of novel coumarin derivatives conjugated to piperidine, morpholine, thiophene and erucic 
acid structures were successfully synthesized, and biological studies of key enzymes, i.e. MAO-B 
and AChE in AD were studied. Molecular modelling investigations of the selected promising 
compounds with MAO-B and AChE provided insight into the binding modes and requirements of 
these structures. The current study showed the coumarin scaffold to be uniquely suitable for 
designing novel lead structures as MTDLs for AD. 
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